3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Breast Neoplasms
158
Lymphoma
156
Precursor Cell Lymphoblastic Leukemia-Lymphoma
130
Lymphoma, Non-Hodgkin
120
Leukemia
119
Leukemia, Lymphocytic, Chronic, B-Cell
116
Multiple Myeloma
115
Lymphoma, Large B-Cell, Diffuse
100
Leukemia, Myeloid, Acute
97
Hodgkin Disease
82
Myelodysplastic Syndromes
78
Lymphoma, Follicular
74
Lymphoma, Mantle-Cell
72
Burkitt Lymphoma
66
Lymphoma, B-Cell, Marginal Zone
52
Melanoma
49
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
48
Neoplasms
45
Recurrence
38
Hematologic Neoplasms
34
Lymphoma, Large-Cell, Immunoblastic
33
Myeloproliferative Disorders
31
Congenital Abnormalities
31
Waldenstrom Macroglobulinemia
30
Neoplasms, Plasma Cell
30
Leukemia, Myelomonocytic, Chronic
30
Lymphoma, B-Cell
29
Primary Myelofibrosis
27
Lymphoma, Large-Cell, Anaplastic
27
Leukemia, Myeloid, Accelerated Phase
26
Interventions
Emapalumab
2
Alemtuzumab
2
tocilizumab
1
Whole-Body Irradiation
1
Methotrexate
1
Etoposide
1
Dexamethasone
1
Data Collection
1
Cytarabine
1
Cyclophosphamide
1
Calcium Dobesilate
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphohistiocytosis, Hemophagocytic
×
Cyclophosphamide
×
Clear all
NCT00368355
2020-01-21
MOHEL
Baylor College of Medicine
Phase 2
Completed
46 enrolled
12 charts